ADAG: Rega marang dodolan Adagene Inc
Adagene develops anti-tumor antibodies while facing fierce competition and the risk of shifting therapeutic approaches. A lack of sales leaves the business dependent on external financing due to the uncertainty of early-stage testing. The current price-to-sales ratio demonstrates valuation volatility, with the value stabilizing at 14.50. Implementing laboratory robotics to accelerate molecule screening could become a key driver in increasing research efficiency.
Rincian analitis perusahaan Adagene (ADAG)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Total Utang marang Modal Adagene|ADAG - Utang jangka dawa marang modal|Tanggungan utang jangka cendhak marang ekuitas adagene.com|ADAG - Gunggung utang perusahaan|Utang-utang marang nilai buku Adagene Corp|ADAG - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Adagene|Likuiditas darurat adagene.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
ADAG - Bathi resik|Proyeksi bathi mangsa ngarep Adagene|ADAG - Pangali P/E|Rasio rega marang bathi mangsa ngarep adagene.com|ADAG - Pangali PEG|Pangali EV/EBITDA Adagene Corp|ADAG - Bathi operasional EBITDA|Bathi resik saben saham sajroning taun lumaku Adagene|ADAG - Bathi saben saham sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan adagene.com|ADAG - Wutah bathi ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Adagene
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:ADAG - Adagene Inc
The P/S ratio determines the market value of a business relative to its generated revenue, measuring the premium for future growth. For Adagene (ADAG), the current P/S valuation reflects the monetization potential of its intellectual property and patents in the field of oncology antibodies. The dynamics of this indicator allow for an assessment of the efficiency of capitalizing future licensing payments. Analyzing this ratio helps investors avoid overpaying for assets at the peak of the market cycle.
Pesaing Adagene
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|PTGX - Multiplikator P/S|IMVT: Multiplikator P/S|Rasio kapitalisasi marang pendapatan KNSA|GRFS (Grifols) - Multiplikator P/S|Multiplikator P/S Adaptive Biotech|Multiplikator P/S CLDX|Aurinia Corp (AUPH) - Multiplikator rega marang pendapatan|Multiplikator P/S BCRX (BioCryst)|veratx.com (VERA) - Rega marang dodolan|DNTH - Rasio rega marang pendapatan|PHVS (Pharvaris NV) - Rasio kapitalisasi marang pendapatan|ABCL: Multiplikator P/S|Rega marang dodolan Tourmaline (TRML)|PGEN (Precigen, Inc.) - Multiplikator P/S|Multiplikator P/S pharming.com|Multiplikator P/S NKTR|Upstream Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ZBIO (Zenas Biopharma, Inc.)|Multiplikator P/S Immunome Bio IMNM|Gossamer Bio, Inc. - Multiplikator P/S|Multiplikator rega marang pendapatan kalvista.com (KALV)|Septerna (SEPN) - Rasio rega marang pendapatan|Rasio rega marang dodolan PVLA (Pieris Pharma)|SVRA (Savara Corp) - Multiplikator P/S|RIGL: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ANAB|Multiplikator P/S astriatx.com (ATXS)|Rasio rega marang pendapatan enGene ENGN|Rasio kapitalisasi pasar marang pendapatan RAPT|JBIO - Rasio rega marang pendapatan|Aclaris Therapeutics, Inc (ACRS) - Kapitalisasi marang pendapatan|KYTX: Multiplikator P/S|tizianalifesciences.com (TLSA) - Multiplikator P/S|Kapitalisasi marang pendapatan CABA|VTYX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S THTX|Koefisien rega marang pendapatan Avalo Therapeutics Inc|Rasio rega marang pendapatan Eledon Pharmaceuticals ELDN|AGEN - Kapitalisasi marang pendapatan|CLYM - Rasio rega marang pendapatan|Zura Bio Ltd (ZURA) - Kapitalisasi marang pendapatan|ATYR (aTyr) - Kapitalisasi marang pendapatan|Ikena Oncology (IMA) - Multiplikator P/S|Rasio rega marang pendapatan Shattuck Labs Inc|Rasio kapitalisasi marang pendapatan EQ (Equillium Bio)|Multiplikator P/S CNTB|IMUX - Rega marang dodolan|Multiplikator P/S ATRA (Atara Bio)|Multiplikator P/S InflaRx NV IFRX|X4 Pharmaceuticals - Multiplikator P/S|ACET (Adicet Bio) - Rasio kapitalisasi marang pendapatan|CELU: Multiplikator P/S|INmune Bio Inc (INMB) - Multiplikator P/S|BRNS (Barinthus Bio) - Multiplikator P/S|KZR - Multiplikator rega marang pendapatan|Multiplikator P/S SABS|AKTX - Rega marang dodolan|Rasio rega marang pendapatan Enlivex Therapeutics Ltd. ENLV|QTTB: Rasio kapitalisasi marang pendapatan|GeoVax Labs Inc - Multiplikator P/S|Rega marang dodolan Edesa Biotech Corp|IBIO: Multiplikator P/S|Carisma Therapeutics Inc. (CARM) - Multiplikator P/S|XTLB (XTL Biopharmaceuticals Ltd.) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan BOLT (Bolt Bio)|Multiplikator P/S HCWB|Multiplikator P/S aptevotherapeutics.com (APVO)|Multiplikator P/S AIM (AIM ImmunoTech Inc.)|Multiplikator rega marang pendapatan Aditxt Inc.|GRI - Rasio rega marang pendapatan|Rasio rega marang dodolan XRTX|HIND: Multiplikator P/S|Revelation Biosciences Corp - Rasio kapitalisasi pasar marang pendapatan|INDP (Indaptus Therapeutics) - Multiplikator P/S|Multiplikator P/S scinai.com|Rasio rega marang pendapatan CalciMedica, Inc. (CALI)|AFMD (affimed.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Allakos ALLK|HOOK - Kapitalisasi marang pendapatan|IGM Bio - Multiplikator P/S|ITOS - Multiplikator P/S|OCEA (Ocean Biomedical) - Kapitalisasi marang pendapatan|TC BioPharm (Holdings) Plc - Rasio kapitalisasi pasar marang pendapatan|THRD (Third Harmonic Bio, Inc) - Multiplikator P/S
